GET DAILY SIGNALSWhy Is SkinHealth Systems (SKIN) Stock Up +30.63% Today?
Key Takeaways
- SKIN shares surged approximately +30.63% to $13.52, up from a prior close of $10.35.
- The rally was driven by the company's third-quarter 2026 earnings report, which showed a sharp recovery in margins and a return to growth in consumables revenue.
- Adjusted EBITDA jumped roughly 50% year over year, and adjusted gross margin expanded 380 basis points to 71.8%.
- The company also retired $103.2 million of 2026 convertible notes, easing a key balance-sheet overhang.
- Despite an EPS miss versus consensus, investors focused on improving profitability and operational momentum.
- Traders are now watching whether equipment sales and EMEA performance stabilize in the quarters ahead.
- For additional detail, explore Price Targets, Earnings, and Forecast pages for SKIN.
- To see how AI-driven strategies are positioning across the market, check out the Trending AI Robots page.
Opening Summary
SkinHealth Systems Inc. (SKIN), formerly The Beauty Health Company, is a medical-aesthetics company best known for its Hydrafacial hydradermabrasion platform and its SkinStylus microneedling system. The company sells systems, treatment consumables, and serums to dermatologists, plastic surgeons, med spas, and aestheticians, generating recurring revenue from consumable refills. On Thursday, shares of SKIN climbed approximately 30.63%, rising $3.17 to $13.52 from a prior-session close of $10.35. The stock's move higher came as investors cheered third-quarter 2026 results that highlighted margin expansion, a return to consumables growth, and meaningful deleveraging, even as headline earnings per share fell short of analyst estimates.
Catalyst Breakdown
Third-Quarter Earnings and Margin Expansion
The primary driver of the rally was SkinHealth's third-quarter 2026 results, reported after the market close on November 5. Net sales came in at $69.2 million, slightly above consensus and down just 2.1% year over year—a meaningful improvement from steeper declines in prior quarters. More importantly, profitability strengthened markedly. Adjusted gross margin rose 380 basis points to 71.8%, the company's third consecutive quarter above 70%, while adjusted EBITDA increased roughly 50% to $13.4 million, or 19.3% of revenue. GAAP operating income turned positive at $5.0 million, marking the second straight quarter of positive operating income. Even though the company posted a GAAP loss per share of $0.14 versus consensus of about $0.06, the market's reaction focused squarely on the margin story and improving operational efficiency.
Consumables Return to Growth
Investors also responded to signs of stabilization in the company's razor-and-blade model. Consumables revenue—the recurring, higher-margin portion of the business—returned to growth, rising 1.2% year over year, with Americas consumables up 4.3%. Management pointed to stronger commercial execution, retrained sales teams, and new product launches, including the HydroClear booster and the relaunched HydroScalp treatment. SkinStylus consumables grew 39% year over year as the brand expanded into six key European markets. This recovery in the recurring-revenue engine was a key bullish signal for a company whose valuation had been pressured by consecutive quarters of declining placements.
Balance-Sheet Deleveraging
A further catalyst was the company's confirmation that it had retired $103.2 million of 2026 convertible notes, eliminating a significant near-term debt overhang that had weighed on sentiment. SkinHealth ended the quarter with roughly $112.4 million in cash and said it maintains sufficient liquidity. By reducing refinancing risk, the company addressed one of the most persistent concerns among investors and analysts.
Market Context and Trading Activity
The magnitude of the move—roughly 30%—reflects a sharp repricing of a beaten-down small-cap name. SKIN had been trading in the low single digits for much of the prior year, and the earnings release provided a catalyst for a rapid re-rating. The stock's surge was accompanied by heavy trading activity typical of an earnings-driven repricing. The move was largely company-specific rather than a broad-market phenomenon, driven by SkinHealth's own financial results and guidance rather than sector-wide sympathy. That said, the shares' rebound also unfolded against a backdrop of resilience in the personal care and consumer-staples segments, with investors rotating toward names showing improving fundamentals.
What Comes Next for SKIN
Looking ahead, the focus shifts to whether SkinHealth can sustain its momentum. Management narrowed full-year 2026 revenue guidance to $281–$287 million, reflecting continued pressure on equipment sales and challenges in the EMEA region, where revenue fell 11.7% year over year. Equipment placements remain the weakest link, with delivery-systems revenue down 9.9% and unit placements down 8.8%. The newly introduced U.S. rental program is designed to lower the upfront capital hurdle for providers and could support future placements, but its impact remains unproven. Analysts will also watch whether adjusted gross margin moderates in the fourth quarter, as management has signaled, due to a higher equipment mix and the non-recurrence of one-time tariff refunds. Risks include intense competition, longer sales cycles, and softer utilization of the installed base.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. Only the strongest performers are featured in this section, giving traders a way to explore algorithmic approaches to the market. Explore the Trending AI Robots page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for SKIN turns negative, indicating new downward trend
SKIN saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In 88 of the 95 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SKIN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for SKIN entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SKIN's RSI Indicator exited the oversold zone, 30 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 65 cases where SKIN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for SKIN just turned positive on November 03, 2026. Looking at past instances where SKIN's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Following a +16.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where SKIN advanced for three days, in 194 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
SKIN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.240) is normal, around the industry mean (21.632). SKIN has a moderately low P/E Ratio (-45.000) as compared to the industry average of (16.880). Projected Growth (PEG Ratio) (0.858) is also within normal values, averaging (1.518). Dividend Yield (0.000) settles around the average of (0.032) among similar stocks. P/S Ratio (0.302) is also within normal values, averaging (1.902).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. SKIN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKIN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HouseholdPersonalCare
Advertisement